Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Advanced Cancer
Interventions: Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 26 more

Conditions: Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions: Rigosertib, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: Pimasertib, Temsirolimus; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Rockland, Massachusetts • Houston, Texas

Conditions: Bicep Tendinitis, Biceps; Tenosynovitis, Bicipital Tendinitis, Left Shoulder, Bicipital Tendinitis, Right Shoulder, Bicipital Tendinitis, Unspecified Shoulder, Biceps Tendon Disorder
Interventions: Dry Needling, Heavy Slow Load Exercise, Rotator cuff and scapular stabilization exercise program, Soft tissue mobilization; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Miami, Florida • Tacoma, Washington

Conditions: Adult Survivors of Childhood Leukemia
Interventions: individual diet & physical activity counselor and website through Healthways at Hopkins, self directed weight loss, questionnaires, fasting blood draw, measurement of height, weight and waist circumference, and blood pressure; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: New York, New York • Memphis, Tennessee

Conditions: Cystic Fibrosis
Interventions: IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more

Conditions: Solid Tumours
Interventions: Savolitinib, Famotidine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cough
Interventions: Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Healthy
Interventions: Olanzapine Tablets 20 mg, Zyprexa® Tablets 20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Cerebrovascular Stroke
Interventions: Fast intervention, Active Monitoring; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pomona, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Dexcom G6 CGM with GTS, POC Blood Glucose Test + Blinded CGM; Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metastatic Renal Cell Carcinoma
Interventions: RAD001, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more

Conditions: Healthy Subjects
Interventions: sevasemten, Verapamil; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Glioma
Interventions: [18F]FMISO-PET with contrast-enhanced MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Critical Illness, Malnutrition, Gastrostomy, Procedural Sequelae, Trauma, Surgery, Mechanical Ventilation
Interventions: noFast: Start tube feeds within 1 hour of procedure; Dietary Supplement
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Febrile Infection, Anthrax
Interventions: TaqMan Bacillus anthracis Detection Kit; Device
Lead sponsor: MRI Global; Industry
Eligibility: 2 Years to 89 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts

Conditions: Healthy
Interventions: Phenytoin (Ascoli), Phenytoin (Vega Baja); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Type 2 Diabetes
Interventions: Ghrelin, Saline; Drug · Other
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity
Interventions: Daily Caloric Restriction (DCR), Intermittent Fasting (IMF); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: Eucalaloric feeding, Acute Fasting, Acute Overfeeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Dry Needling and Exercise Versus Traditional Physical Therapy for Biceps Tendinitis

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

Exercise and QUality Diet After Leukemia: The EQUAL Study

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

Fast Arm Motor Skill Training in Chronic Stroke Survivors

Dexcom Continuous Glucose Monitoring in Long-term Care

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas

RCT: Early Feeding After PEG Placement

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

Febrile Whole Blood Specimen Collection and Testing

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

Metabolic Syndrome Feasibility Study

The Effect of Time-restricted Eating on Liver Metabolism

Preprandial Ghrelin Effect

Intermittent Fasting Versus Daily Caloric Restriction for Weight Loss

Thermogenenic Responses to Fasting and Overfeeding in Women